To determine the efficacy and safety of zoledronic acid therapy in the prevention and treatment of postmenopausal osteoporosis compared to placebo or active comparator (other bisphosphonates).
This is a protocol.
Intravenous zoledronate for postmenopausal osteoporosis
You may also be interested in:
- Pharmacological interventions for preventing bone density loss in critically ill people
- Pharmacologic interventions for preventing and treating periprosthetic osteoporosis following total hip arthroplasty
- Bisphosphonate therapy for children and adolescents with secondary osteoporosis.
- Etidronate for preventing fractures caused by osteoporosis in postmenopausal women
- Calcitonin for preventing and treating corticosteroid-induced osteoporosis
Health topics: